AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00246740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: In addition to standard care, patients received oral administration of placebo twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.
Study NCT00528697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-089
Description: Subjects will take 0.5 and 1 and/or 5 and/or 10 mg ABT-089 tablets (actual dose based on weight) once daily for 8 weeks.
Study NCT02398591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to JNJ 53718678 will be orally administered once on Day 1.
Study NCT00528697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atomoxetine
Description: Subjects will take 10, and/or 18 and/or 25 mg atomoxetine tablets once daily for 8 weeks.
Study NCT00528697 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subject will take a tablet once daily for 8 weeks
Study NCT00522899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 1
Description: Aerobic exercise plus computer-based mental activity training: both 3 days/week, 60 minutes/session for 12 weeks.
Study NCT00522899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 2
Description: Aerobic exercise plus educational DVDs: both 3 days/week, 60 minutes/session for 12 weeks.
Study NCT00522899 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group 2
Description: Aerobic exercise plus educational DVDs: both 3 days/week, 60 minutes/session for 12 weeks.
Study NCT00522899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 3
Description: Stretching/toning exercise group plus computer-based mental activity training: both 3 days/week, 60 minutes/session for 12 weeks.
Study NCT00522899 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group 3
Description: Stretching/toning exercise group plus computer-based mental activity training: both 3 days/week, 60 minutes/session for 12 weeks.
Study NCT00522899 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group 4
Description: Stretching/toning exercise group plus educational DVDs: both 3 days/week, 60 minutes/session for 12 weeks.
Study NCT00548496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-751689
Description: SB-751689
Study NCT00548496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match
Study NCT01212302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimizing ASA and clopidogrel treatment
Description: ASA 100 mg, ASA 300 mg, ASA 500 mg~Clopidogrel 75 mg, Clopidogrel 150 mg, Ticlopidine 2x 250 mg, Prasugrel 10 mg. Intervention List:~In the case of clopidogrel low-response, the maintenance dose was doubled (repeated loading dose followed by 150 mg daily), and when still ineffective ticlopidine or prasugrel, if available and not contraindicated, were used. ASA low-responders were treated by increasing the dose to 300 mg in a first step or to 500 mg ASA when the first modification was not sufficient.
Study NCT04212676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body Awareness Therapy
Description: The BAT for the participants was based on the works of Roxendal and Dropsy. Activities include relaxation exercises, breathing exercises, floor exercises for trunk and pelvic movements, weight transfer using extremities and proprioceptive movements. Movements will be made in various positions to determine the centerline of the body. All exercises will be started in the supine position to maximize proprioceptive motion feedback and minimize energy requirements during tasks. Movements will be taught in a series of lessons over a period of 8 weeks with advance advancement of selected movements depending on participant comfort.
Study NCT04212676 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation
Description: Diaphragmatic breathing exercise Thoracic expansion exercises (Chest breathing and bilateral segmental breathing exercises) Inductive spirometry (Triflo®) exercise Cough development techniques
Study NCT04212676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Diaphragmatic breathing exercise Thoracic expansion exercises (Chest breathing and bilateral segmental breathing exercises) Inductive spirometry (Triflo®) exercise Cough development techniques
Study NCT01710449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perfluorinated gas/oxygen mixture
Description: Subjects are imaged with MRI one time in an proof of concept study for the use of perfluorinated gas / oxygen mixtures as an MRI contrast agent for lung function.
Study NCT03233321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry cold application
Description: Dry cold application using ice bag (Crushed ice was filled in ice bag with ½ table spoon of salt and then covered by clean linen to prevent moisture) was placed over the injection site for about 20 minutes.
Study NCT01227330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication adherence intervention
Description: 12-week behavioral feedback intervention to improve adherence to statin medication
Study NCT01227330 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention-control
Description: Health education visits that are unrelated to medications or cholesterol, provided on the same visit schedule as the intervention group
Study NCT04858165 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: MY GERYFS PROTOCOL
Description: The MY GERYFS will be introduced through a guideline document, dissemination through the department of nursing, notices on the intranet and provision of large signs indicating that MY GERYFS are in progress and the times of meals for each ward. The developed protocol in phase 1 and 2 will be tested in single-centre in a before and after study for its feasibility and safety. In the pre-study, patients will be given usual care. In the post-study, patients will care according to the developed protocol. Clinical outcomes such as malnutrition risk, medical background, anthropometry data, nutrition-focused physical findings, dietary intake, mealtime barrier, Hospital Foodservices satisfaction will be recorded.
Study NCT03311711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPIRIT-in person
Description: The SPIRIT-in person intervention adapted for dementia will include one session and will be conducted in a private room at the clinic. SPIRIT is a structured psychoeducational intervention, targeting both patient and surrogate. The SPIRIT intervention assists patients in clarifying their end-of-life preferences and helps surrogates understand the patient's wishes and prepare for the surrogate role. The intervention is expected to last 45-60 minutes.
Study NCT03311711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPIRIT-remote
Description: The SPIRIT-remote intervention adapted for dementia will include one session and will be conducted through teleconference. SPIRIT is a structured psychoeducational intervention, targeting both patient and surrogate. The SPIRIT intervention assists patients in clarifying their end-of-life preferences and helps surrogates understand the patient's wishes and prepare for the surrogate role. The intervention is expected to last 45-60 minutes.
Study NCT03311711 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will receive the usual care that is provided through the clinic they receive care through. This may include completing advanced directives, referral to a support group, or referral to a social worker for further discussion about end of life issues.
Study NCT03233321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sub cutaneous injection (low molecular weight heparin)
Description: sub cutaneous injection (low molecular weight heparin) has been administered on injection site
Study NCT03145688 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Physical Activity Planning
Description: Families will receive the same guidelines as the standard education control group but will also be provided with family physical activity planning material. This material will include a skill training content workbook on how to plan for family physical activity. The material includes a brainstorming exercise for parents where they list physical activities they think their children have found fun in the past, as well as activities that they would find enjoyable to do as a family. We will provide this material as prompts/suggestions. Families will be instructed to plan for when, where, how, and what physical activity will be performed \& then track their physical activity. These aspects will be re-introduced and discussed at week 6 and week 12 in booster sessions
Study NCT03145688 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Physical Activity Habit Formation
Description: Families will receive the same content as the education control condition and the physical activity planning condition but with additional material on creating physical activity support habits. A key component of the habit section will be based on planning for context-dependent repetition, with pointers on how to maintain repetition as habit forms. The importance of creating cues for parental support of child physical activity is then outlined. Cues will also be considered factors that a) can precede the support activity but b) not be present very often when the activity is not to be performed. We will suggest that cues that have repeated exposure during times when family physical activity is not present Parents will then be asked to brainstorm and create a plan of consistency and cues with the workbooks provided. These aspects will be re-introduced and discussed at week 6 and week 12 in booster sessions.
Study NCT00725062 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD4+CD25+ regulatory T cells
Description: Cohort 1 will receive 3 x 10\^6 CD4+CD25+ cells/kg, Cohort 2 will receive 1 x 10\^7 CD4+CD25+ cells/kg, Cohort 3 will receive 3 x 10\^7 CD4+CD25 cells/kg
Study NCT00725062 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Occurs on Day 0 of study - HLA-identical sibling donor peripheral blood progenitor cell (PBPC) transplantation
Study NCT01656265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 197
Description: Daily repeating dose of oral ARQ 197, twice a day just after meals. Dose of ARQ 197 will be escalated according to 3+3 rule.
Study NCT03195309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Compare different concentration of ropivacaine and fentanyl for elective Cesarean delivery post operative pain control.
Study NCT01724658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate
Description: testosterone undecanoate 40 mg orally twice a week
Study NCT01724658 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo orally twice a week with progynova 1 mg oral daily
Study NCT01401634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral water
Description: 2 Liters of water given orally
Study NCT01401634 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intravenous normal saline
Description: 2 Liters Intravenous normal saline
Study NCT03638232 — intervention group
Intervention type: OTHER
Intervention: Administrative data
Description: Gender Birthdate Department and town of residence Date of death Affiliation to french Universal Health Coverage
Study NCT03638232 — intervention group
Intervention type: OTHER
Intervention: Medical data
Description: Long term affection code, number and medical codification Date of onset and end of care Codification of medical acts and consultation (With common classification of medical acts)
Study NCT03638232 — intervention group
Intervention type: OTHER
Intervention: Drug exposition data
Description: Speciality of prescribing physician CIP code of drug Name of speciality prescribed Date of deliverance Date of prescription Number of treatment box delivered
Study NCT02079987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ED-to-home care transition intervention
Description: The Area Agency on Aging coach's role is to build self-management capabilities for the patient and their caregiver. During each contact, the coach reviews the four components of the Care Transition Intervention: 1: Follow-up Medical Visit. 2: Knowledge of Red Flag Symptoms. 3: Medication Reconciliation. 4: The Personal Health Record (PHR). The coach assists patients use the PHR to document and maintain vital information and to communicate with providers.
Study NCT02079987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Patients randomized to usual care will receive verbal and written discharge instructions from the treating ED physician and nurse as is the standard of care.
Study NCT03428178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAAV2-ND4
Description: rAAV2-ND4 of vitreous cavity injection
Study NCT03147729 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiofrequency non ablation
Description: Use of radiofrequency
Study NCT03195309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Compare different concentration of ropivacaine and fentanyl for elective Cesarean delivery post operative pain control.
Study NCT02707263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous continuous infusion of heparin (IV UFH)
Study NCT02707263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous Heparin
Study NCT02845167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative exercise
Description: Patients will perform 3 consecutive days of 60 min submaximal cycling exercise at a moderate exercise intensity. During the 60 min of exercise, patients will be provided with three equally spaced 3min rest periods
Study NCT03229642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rTMS
Description: The stimulator device was a Magstim super rapid magnetic stimulator (Magstim Company, Ltd., Wales, United Kingdom) with 4 booster modules equipped with a 70-mm air-cooled figure-eight-shaped coil. We performed rTMS on the left dorsolateral prefrontal cortex (DLPFC).The TMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions. The sham group was administered rTMS with the same parameters, but using a figure-of-eight sham coil.
Study NCT03229642 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: The stimulator device was a Magstim super rapid magnetic stimulator (Magstim Company, Ltd., Wales, United Kingdom) with 4 booster modules equipped with a 70-mm air-cooled figure-eight-shaped coil. We performed rTMS on the left dorsolateral prefrontal cortex (DLPFC).The TMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions. The sham group was administered rTMS with the same parameters, but using a figure-of-eight sham coil.
Study NCT02001753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CMR
Study NCT02001753 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CMR
Study NCT01879358 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-eluting stent
Study NCT01318005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Contraceptive: Ortho-Novum® 1/35
Description: Oral Contraceptive: Ortho-Novum® 1/35, pill, 2-3 mos, daily.
Study NCT01318005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Contraceptive: Ovcon® 35
Description: Oral Contraceptive: Ovcon® 35, pill, 2-3 mos, daily.
Study NCT01318005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Contraceptive: Microgestin Fe® 1/20
Description: Oral Contraceptive: Microgestin Fe® 1/20, pill, 2-3 mos, daily.
Study NCT02626195 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nutritional support program
Description: Nutritional support program is briefly described below.~Interval: 5-10 days Contents: admission is required~* Calories: 30-35Kg, via enteral or parenteral~* Protein: 1.2-1.5g/Kg~* Lipid : 1-1.5g/Kg~* Mineral and vitamins supply~* Blood glucose control~* Daily monitoring by dietician and specialized nurse
Study NCT02758340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Women would be given misoprostol tablet by mouth
Study NCT02758340 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: foley's balloon catheter
Description: foley's balloon catheter would be inserted through vagina into cervix.
Study NCT01318109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin and metformin
Description: Alogliptin 12.5 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks.
Study NCT01318109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin and metformin
Description: Alogliptin 25 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks.
Study NCT01318109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 250 mg, tablets, orally, twice or three times daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks.
Study NCT03651596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Messaging Intervention Group
Description: The newly developed intervention messages will be sent to individuals assigned to the intervention group during the study.
Study NCT03651596 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard mHealth Messaging Group
Description: Standard mHealth messages will be sent to individuals assigned to the active control group during the study.
Study NCT04642339 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gam-COVID-Vac
Description: Gam-COVID-Vac combined vector vaccine, 0,5ml/dose+0,5 ml/dose prime-boost immunization with component I (rAd26-S) and component II (rAd5-S) with 21 days interval
Study NCT04642339 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01739179 — intervention group
Intervention type: PROCEDURE
Intervention: VP Shunt Surgery for laparoscopic insertion of the peritoneal catheter
Description: Patients in this Study Arm will receive a VP Shunt inserted laparoscopically
Study NCT01739179 — intervention group
Intervention type: PROCEDURE
Intervention: VP Shunt Surgery for open insertion of the peritoneal catheter
Description: Patients in this Study Arm will receive a VP Shunt inserted openly
Study NCT00419380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dornase alfa (Pulmozyme®)
Description: This study will compare two treatment arms. Patients will be randomized to either traditional treatment (Ofloxin)or to experimental treatment \[dornase alfa (Pulmozyme®)\]. Each arm will have subjects instilling 5 drops twice daily for 7 days to the affected ear.
Study NCT04430244 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep anterior lamellar keratoplasty
Description: Deep anterior lamellar keratoplasty using dehydrated corneas
Study NCT04430244 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep anterior lamellar keratoplasty
Description: Deep anterior lamellar keratoplasty using standard organ culture stored corneas
Study NCT03260387 — intervention group
Intervention type: PROCEDURE
Intervention: TPIAT
Description: The entire pancreas is removed to treat the pain of chronic pancreatitis, and the islets are infused back into the patient to reduce diabetes risk after surgery.
Study NCT00637988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 40mg twice daily
Study NCT03945708 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CytoSorb
Description: Addition of a hemofilter to the cardiopulmonary bypass circuit
Study NCT01806363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan 80mg
Study NCT01806363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone 25mg
Study NCT00610831 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIRECTVIEW CR Mammography
Description: 4 views screening mammogram
Study NCT00637988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Study NCT00689871 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Natrelle(TM) Silicone-Filled Breast Implants
Description: Breast implant surgery
Study NCT01154374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEBO Wound Ointment
Description: Topical application twice daily
Study NCT01154374 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (sterile saline moistened gauze)
Study NCT00742768 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K2 in softgel
Description: 4 softgel capsules containing 45 µg MK-7 and 5 µg vitamin D3 per capsule and 4 softgel capsules containing 30 µg MK-4 per capsule